Finansies
Finansies
TuisTMOS34 • BVMF
Thermo Fisher Scientific BDR
R$52,81
2 Apr., 21:14:30 GMT-3 · BRL · BVMF · Vrywaring
AandeelBR-gelyste effekHoofkantoor in VSA
Vorige sluiting
R$52,81
Dagwisseling
R$52,81 - R$53,17
Jaarwisseling
R$44,25 - R$71,92
Markkapitalisasie
182,57 mjd USD
Gemiddelde volume
5,06 k
P/V-verhouding
-
Dividend-opbrengs
-
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(USD)Des. 2025J/J-verandering
Inkomste
12,22 mjd7,20%
Bedryfskoste
2,46 mjd-4,80%
Netto inkomste
1,96 mjd7,32%
Netto winsgrens
16,080,12%
Wins per aandeel
6,577,70%
EBITDA
3,31 mjd10,32%
Effektiewe belastingkoers
7,21%—
Totale bates
Totale aanspreeklikheid
(USD)Des. 2025J/J-verandering
Kontant en korttermynbeleggings
10,10 mjd81,42%
Totale bates
110,34 mjd13,38%
Totale aanspreeklikheid
56,81 mjd19,22%
Totale ekwiteit
53,54 mjd—
Uitstaande aandele
371,48 m—
Prys om te bespreek
0,37—
Opbrengs op bates
6,06%—
Opbrengs op kapitaal
7,11%—
Netto kontantverandering
(USD)Des. 2025J/J-verandering
Netto inkomste
1,96 mjd7,32%
Kontant van bedrywe
3,46 mjd5,08%
Kontant van beleggings
891,00 m4 355,00%
Kontant van finansiering
3,53 mjd196,18%
Netto kontantverandering
7,87 mjd1 348,89%
Beskikbare kontantvloei
2,20 mjd-12,06%
Meer oor
Thermo Fisher Scientific Inc. is an American life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation, Alfa Aesar, Affymetrix, FEI Company, BD Advanced Bioprocessing, and PPD. It ranked 104th on the Fortune 500 list based on its 2024 annual revenue of $42.879 billion. Thermo Fisher announced a $2 billion investment over four years in the U.S., including $1.5 billion for expanding manufacturing capacity and $500 million for R&D investment. This initiative aims to bolster domestic biotech manufacturing, create high-paying jobs, and reinforce the U.S. healthcare supply chain. Wikipedia
Gestig
1956
Werknemers
125 000
Search
Vee soektog uit
Maak soekkassie toe
Google-programme
Hoofkieslys